Worcester, MA, January 13, 2006--- One of the world's leading authorities on embryonic stem cells, Robert Lanza, M.D., VP, Medical & Scientific Development for Advanced Cell Technology (OTCBB: ACTC), has released a comprehensive new book on embryonic stem cell research and its real world applications, *Essentials of Stem Cell Biology* (Academic Press, November 2005, Hardcover).
*Essentials of Stem Cell Biology* is an abridged version of the bestselling reference, *Handbook of Stem Cells*, a two-volume set. The new work incorporates into a single volume all the essential subject matter of the original two-volume edition. The material in the first set has been reworked in an accessible format suitable for both students and general readers interested in following the latest advances in stem cells, and includes numerous full color presentations. The new format is designed to promote better understanding of the scientific and ethics issues posed by adult and embryonic stem cell research and the associated real-life applications.
Dr. Lanza, who also serves as adjunct Professor at the Institute of Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, is in great demand within the scientific community and the media, not only for his groundbreaking work but also for his unique ability to cut through the confusion and controversy, and clearly articulate the issues and delineate the benefits surrounding the important research he and others are doing with embryonic stem cells for the betterment of humanity.
Doctors Lanza and West have both been widely quoted on the world stage, including recent media interviews for leading publications and television networks in the U.S. and South Korea, which looked to them for their expert input on the scientific and ethical issues involved in recent breaking-news events.
*Essentials of Stem Cell Biology* is co-edited by thought leaders John Gearhart, Johns Hopkins University School of Medicine, Baltimore, Maryland; Brigid Hogan, Duke University Medical Center, Durham, North Carolina; Douglas Melton, Howard Hughes Medical Institute, Harvard University, Cambridge, Massachusetts; Roger Pedersen, Department of Surgery, University of Cambridge and Addenbrooke's Hospital, Cambridge, U.K.; James Thomson, Wisconsin Regional Primate Research Center, University of Wisconsin, Madison, Wisconsin, E. Donnall Thomas, Director Emeritus, Fred Hutchinson Cancer Research Center, Seattle, Washington, and Michael West, Chairman, President and Chief Scientific Officer of Advanced Cell Technology.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company is currently headquartered in Worcester, Massachusetts. For more information about the company, visit "www.advancedcell.com":http://www.advancedcell.com.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2005.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.